MDACC Study No:2011-1157 ( NCT No: NCT01827111)
Title:Phase II Study of Abraxane Plus Ipilimumab in Patients with Metastatic Melanoma
Principal Investigator:Adi Diab
Treatment Agent:ABI-007; Ipilimumab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
ipilimumab and ABI-007 (abraxane) can help to control metastatic melanoma. The
safety of this drug combination will also be studied.

Ipilimumab is designed to increase the immune system's ability to fight cancer.

ABI-007 is designed to stop cancer cells from making new DNA (the genetic
material of cells). This may stop the cancer cells from dividing into new
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:ABI-007
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Celgene
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Adi Diab
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults